The QualityStocks Daily Tuesday, March 2nd, 2021

Today's Top 3 Investment Newsletters

Tip.us(DVLP) +167.86%

QualityStocks(KPIFF) +163.64%

Trades Of The Day(RKT) +71.19%

The QualityStocks Daily Stock List

Nextech AR Solutions Corp. (OTCQB: NEXCF) (NEO: NTAR) (CSE: NTAR) (FSE: N29)

TradersPro, QualityStocks, MarketClub Analysis and CFN Media Group reported earlier on Nextech AR Solutions Corp. (NEXCF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Nextech AR Solutions (OTCQB: NEXCF) (NEO: NTAR) (CSE: NTAR) (FSE: N29), a leading provider of virtual and augmented reality (“AR”) experience technologies and services for eCommerce, education, advertising, conferences, and events, today announced the launch of its Ad Network. According to the update, the Ad Network generated very positive results at recently held virtual and hybrid events for Repticon, which puts on 100 events annually, and the North Carolina Association of Zoning Officials (“NCAZO”) Annual Conference. The company is utilizing its owned and operated virtual event platform audience, which hosts thousands of specialized events that allow for targeted ads based on people's interests, behaviors, location, and demographics.

“We’re thrilled to see such impressive, early results from our Ad Network piloted across two unique events. We’re proud to have built a platform, which increases engagement, interactive experiences and learning opportunities for sponsors and attendees of both hybrid and fully virtual events,” said Nextech AR’s President of Advertising, Hareesh Achi. “With Repticon and NCAZO, we’ve showcased that our ad network can drive results for any type of event, from virtual to hybrid to in-person. Trade shows, consumer expos and professional conferences are the future of targeted, impactful advertising and offer incredibly cost-effective investment to brands. Based on the success of these initial pilot events and customer feedback, Nextech is well-positioned to be a leader in this space.”

To view the full press release, visit http://ibn.fm/k750j

Nextech is one of the leaders in the rapidly growing augmented reality market estimated to grow from $10.7 billion in 2019 and projected to reach $72.7 billion by 2024 according to Markets & Markets Research; it is expected to grow at a CAGR of 46.6% from 2019 to 2024. The company is pursuing four verticals: Virtual Experience Platform (“VXP”), an advanced augmented reality and video learning experience platform for events; ARitize(TM) for eCommerce; ARitize 3D/AR advertising platform, the industry's first end-to-end solution whereby the company will leverage its 3D asset creation into 3D/AR ads; and ARitize Hollywood Studios, a project that produces immersive content using 360 video and augmented reality as the primary display platform. For more information about the company, please visit www.NextechAR.com.    

Nextech AR Solutions Corp. (NEXCF), closed Tuesday's trading session at $4.16, off by 0.297191%, on 128,035 volume with 421 trades. The average volume for the last 3 months is 391,831 and the stock's 52-week low/high is $3.70050001/$5.41120004.

MICT Inc. (NASDAQ: MICT)

StockMarketWatch, TradersPro, TraderPower, StreetInsider, MarketBeat, Profitable Trader Authority, OTCtipReporter, PennyStockProphet, TopPennyStockMovers, HotOTC, Marketbeat.com, Buzz Stocks, Penny Pick Finders, Penny Stock 101, PennyStockLocks, BUYINS.NET, PennyStockScholar, QualityStocks, StockOnion, StockRockandRoll, Wall Street Resources and PoliticsAndMyPortfolio reported earlier on MICT Inc. (MICT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

MICT Inc. (NASDAQ: MICT) is a holding company which is engaged in the design, manufacture, development and sale of mobile computing devices and software which offer field workforces and fleet operators computing solutions in demanding work environments. The firm is part of the Data Storage Systems Manufacturing Industry.

MICT Inc. is also focused on online investment and wealth management services and brokerage for equity trading as well as the sale of insurance products in foreign markets.

MICT Inc. works in the burgeoning commercial telematics resource management market in Europe and the U.S. MICT Inc. is based in Montvale, New Jersey and was established on January 31, 2002. Before changing its name in July 2018, the firm was referred to as Micronet Enertec Technologies Inc.

The firm operates through the following other subsidiaries; Micronet Ltd and GFH Intermediate Ltd (Global Fintech Holdings), which offers high growth sectors in the international Financial Technology space proprietary trading tech platforms as well as mobile computing solutions. Its SmartHub product provides the following services to the company’s consumers: a driver assistance system, driver recognition, fuel efficiency, identifying and preventing driver fatigue, preventive maintenance and recognizing driver behavior.

MICT Inc. recently acquired Huapei Global Securities Ltd, which provides the firm with an even larger consumer base to acquire customers from. With China’s online retail securities market projected to reach $30.3 trillion by 2022 and the firm’s newly acquired experienced management team, MICT Inc. is bound to make a killing on the market.

MICT Inc. (MICT), closed Tuesday's trading session at $2.96, up 4.9645%, on 16,558,821 volume with 39,440 trades. The average volume for the last 3 months is 4,767,315 and the stock's 52-week low/high is $0.43869999/$8.4499998.

Sio Gene Therapies Inc. (NASDAQ: SIOX) (FRA: 6YY)

We reported earlier on Sio Gene Therapies Inc. (SIOX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Sio Gene Therapies Inc. (NASDAQ: SIOX) (FRA: 6YY) is a biopharmaceutical firm which acquires, develops and markets gene therapies for various debilitating neurodegenerative ailments.

Sio Gene Therapies was established on October 31, 2014 and has its headquarters in New York. The company recently changed its name from Axovant Gene Therapies Ltd. in November 2020. The firm serves consumers globally.

Sio Gene Therapies operates through 7 subsidiaries which are wholly owned. They include Axovant Sciences Europe Ltd, Axovant Treasury Holdings Inc., Axovant Treasury Inc., Axovant Sciences America Inc., Axovant Sciences GmbH, Axovant Holdings Ltd and Axovant Sciences Inc. The firm has business operations in New York as well as in Basel, Switzerland and has a license agreement with the University of Massachusetts Medical School and Oxford BioMedica.

The firm has in development a range of product candidates indicated for the treatment of debilitating ailments, such as GM1 and GM2 gangliosidosis; which includes Sandhoff disease and Tay-Sachs disease, GM1 gangliosidosis and Parkinson’s disease.

Sio Gene Therapies programs include the AXO-AAV-GM2, AXO-Lenti-PD and AXO-AAV-GM1 program. The latter program involves the treatment of GM1 gangliosidosis while the former program is indicated for the treatment of GM2 gangliosidosis. The AXO-Lenti-PD program is indicated for the treatment of Parkinson’s disease.

Sio Gene Therapies recently announced the commencement of their AXO-AAV-GM2 investigation gene therapy for GM2 gangliosidosis treatment. Positive results will allow the firm to develop a treatment for children affected by this fatal and rapidly progressive disease, making the treatment the first of its kind.

Sio Gene Therapies Inc. (SIOX), closed Tuesday's trading session at $2.68, off by 7.2664%, on 2,894,552 volume with 9,233 trades. The average volume for the last 3 months is 2,612,735 and the stock's 52-week low/high is $1.40999996/$5.73999977.

vTv Therapeutics Inc. (NASDAQ: VTVT) (FRA: 5VT)

MarketBeat, MarketClub Analysis, StockMarketWatch, Kiplinger Today, BUYINS.NET, InvestorPlace, TraderPower, TopPennyStockMovers, StreetInsider, QualityStocks, PoliticsAndMyPortfolio, TradersPro, Barchart, Marketbeat.com, Wealth Insider Alert, The Online Investor, Jason Bond, Trades Of The Day and SmallCapVoice reported previously on vTv Therapeutics Inc. (VTVT), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

vTv Therapeutics Inc. (NASDAQ: VTVT) (FRA: 5VT) is a biopharmaceutical firm which operates in the U.S. healthcare sector and is engaged in the discovery and development of oral drug candidates.

vTv Therapeutics was established on April 2, 2015 and is a MacAndrews & Forbes Incorporated subsidiary. The firm, which is based in High Point, North Carolina changed its name from TransTech Pharma to vTv Therapeutics Inc. in May 2015.

vTv Therapeutics has a research and license agreements with Columbia University, Novo Nordisk A/S, JDRF International, Newsoara Biopharma Co. Ltd and Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. It also has a license agreement to develop and market its PPAR delta agonist program with Reneo Pharmaceuticals Inc., which include its HPP593 compound.

The firm is currently developing an orally administered antagonist known as Azeliragon, which is undergoing phase 2 clinical trials for mild Alzheimer’s treatment. Other products from vTv Therapeutics include TTP273; which recently concluded its phase 2 clinical trials for type 2 diabetes treatment, TTP399; a glucokinase activator which finalized its phase 2b clinical trial for type 1 diabetes treatment and phase 2 clinical trials for type 2 diabetes. Additionally, the firm is developing HPP3033, HPP971 AND HPP737 for treating chronic disease and inflammatory disorders.

vTv recently published its TTP399 clinical trial results which demonstrated a decrease in symptomatic or severe hypoglycemia as well as significant declines in HbA1c. This suggests that this product may be used to decrease hypoglycemia and lower HbA1c without growing an individual’s risk of ketosis. If future trials produce positive results which result in the drug being approved by the FDA, individuals who suffer from type 1 diabetes will be provided with an alternative way to achieve optimal glycemic control.

vTv Therapeutics Inc. (VTVT), closed Tuesday's trading session at $2.35, off by 6.00%, on 1,843,105 volume with 6,321 trades. The average volume for the last 3 months is 5,532,491 and the stock's 52-week low/high is $1.44000005/$4.75.

Xtant Medical Holdings Inc. (NYSE American: XTNT) (OTC: XTNTW) (FRA: XMS)

StockMarketWatch, OTC Picks, Marketbeat.com, BUYINS.NET, OTC Markets Group, Promotion Stock Secrets, StreetInsider, TraderPower, QualityStocks, Stock Beast, Wall Street News Alert, MarketClub Analysis, Wall Street Mover, MarketBeat, Investing Futures, HotOTC, DreamTeamNetwork and PoliticsAndMyPortfolio reported beforehand on Xtant Medical Holdings Inc. (XTNT), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter. 

Xtant Medical Holdings Inc. (NYSE American: XTNT) (OTC: XTNTW) (FRA: XMS) is a firm involved in the acquisition, development, manufacture and marketing of biomedical devices and regenerative medicine products for neurological and orthopedic surgeons in both domestic and global markets, indicated for the treatment of deformity, traumatic and degenerative conditions.

Xtant Medical was known as Bacterin International Holdings before changing its name in July 2015. The firm, which serves consumers in the U.S., was established in 2006 and is based in Belgrade, Montana.

Xtant Medical Holdings manufactures surgical instruments and implants under the Silex, Axle, Xpress, Calix and IRIX-C brands. This firm is also engaged in developing and manufacturing orthopedic biomaterials which are used for skeletal reconstructive procedures such as joint surgery and bone grafts.

In addition to other allografts, Xtant Medical Holdings’ biomaterial portfolio is made up of a stabilization dowel used in spinal procedures known as OsteoLock, 3Demin products, OsteoSponge SC, hMatrix, OsteoSponge; which is a bone void filler manufactured from human bone, BacFast Hd, OsteoSelect Plus DBM putty, OsteoWrap and OsteoSelect DBM putty. The firm’s products help treat spinal disease and promote bone healing.

Xtant Medical recently reported its private placement worth $20 million, with its CEO stating that the capital provided the firm with additional resources which will be used to achieve strategic goals and progress its central growth measures while also driving greater shareholder value and improving every patient’s quality of life.

Xtant Medical Holdings Inc. (XTNT), closed Tuesday's trading session at $3.85, off by 5.868%, on 2,595,798 volume with 13,250 trades. The average volume for the last 3 months is 4,107,006 and the stock's 52-week low/high is $0.550000011/$6.57999992.

Worksport Ltd. (WKSP)

QualityStocks and InvestorPlace reported earlier on Worksport Ltd. (WKSP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Worksport Ltd. is a manufacturer of high quality, functional, and aggressively priced tonneau/truck bed covers for light trucks. These include the F150, Sierra, Silverado, Canyon, RAM, and Ford F-Series. The Company’s latest innovation is TerraVis™. This is a solar-based tonneau cover. It utilizes the sun to produce onboard power for pickup trucks. Currently, Worksport tonneau covers serve customers in the United States and Canada.

Worksport is headquartered in Vaughan, Ontario. The Company formerly went by the name Franchise Holdings International, Inc. It changed its corporate name to Worksport Ltd. in August of this year. Worksport’s shares trade on the OTC Markets Group’s OTCQB.

Worksport offers Worksport Tri Fold, a soft folding tonneau cover; and Worksport Smart Fold, a rear smart latch system. Furthermore, the Company offers Worksport Quad-Fold. This is a vinyl wrapped tonneau cover to fold in four sections. It also offers Worksport Forte GEN2 tonneau covers.

Recently, Worksport announced it engaged Thermal Technology Services Canada to test its TerraVis™ solar panel technology to increase its efficiency. The tests were launched as Worksport recently made its first public disclosure about TerraVis™. It is the very first solar-powered advanced folding truck bed tonneau cover system to be a fusion of innovative solar power, storage, as well as delivery.

The platform leverages a standard pick-up truck’s practical capabilities. This while also using the power of more sustainable and renewable energy. Proprietary, high efficiency solar panels built into the rugged tonneau cover will collect the sun's rays and store energy in numerous battery banks.

Thermal Technology’s Temperature Modulation enhances different metals’ performance. As a result, it strengthens Zinc, Silver, and Copper components of Worksport’s TerraVis™ by realigning their molecular structure. In addition, Worksport’s intention is to pursue testing the metal components and hardware of TerraVis™ solar panels to realize greater strength and integrity. The Company stated it will continue to collaborate with Thermal Technology and engage in further testing and product development.

Worksport Ltd. (WKSP), closed Tuesday's trading session at $0.5195, up 49.4964%, on 13,094,983 volume with 3,636 trades. The average volume for the last 3 months is 2,726,703 and the stock's 52-week low/high is $0.050099998/$0.819999992.

Digital Locations, Inc. (DLOC)

We reported  previously on Digital Locations, Inc. (DLOC), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Digital Locations, Inc. is a developer of cell tower sites for the 5G revolution. The Company plans to partner or co-develop a portfolio of cell tower sites to help meet the demands of 5G networks. Its aim is to become a “landlord” of tomorrow’s wireless communications assets.

The Company formerly went by the name Carbon Sciences, Inc. It changed its name to Digital Locations, Inc. in September of 2017. Founded in 2006, Digital Locations has its head office in Santa Barbara, California.

Mr. William E. Beifuss, Jr. is President and Chief Executive Officer (CEO) of Digital Locations. Mr. Beifuss is a business executive with considerable real estate development experience. He has been the President, acting Chief Financial Officer (CFO), Secretary, and a Director of the Company since May 2013. Furthermore, he served as Interim CEO of the Company from May 2017 to July 2017 and as CEO of the Company from May 2013 to March 2016.

The expectation is that the 5G wireless networks will be 100 times faster than current 4G LTE networks. Many new 5G broadcast locations are needed because high frequency 5G signals cannot travel farther than 100 meters. The estimation is that more than 1 million new 5G cell towers must be added in the U.S. alone.

5G is the 5th generation mobile network. The prior generations are 1G, 2G, 3G and 4G. 1G delivered analog voice and 2G introduced digital voice. 3G brought mobile data and 4G LTE brought in the era of mobile Internet.

Recently, Digital Locations announced that its application was accepted to perform research on Powder (the Platform for Open Wireless Data-driven Experimental Research). This is the future of wireless networking in a city-scale “living laboratory.”

Powder is run by the University of Utah in partnership with Salt Lake City and the Utah Education and Telehealth Network. Powder will deploy state-of-the-art off-the-shelf equipment. In addition, it will deploy pioneering radio hardware and software undergoing development by the RENEW team lead by Rice University.

Digital Locations, Inc. (DLOC), closed Tuesday's trading session at $0.061, up 41.8605%, on 36,986,011 volume with 1,848 trades. The average volume for the last 3 months is 11,039,721 and the stock's 52-week low/high is $0.003449999/$0.349999994.

Magellan Gold Corporation (MAGE)

QualityStocks, PennyStockMoneyTrain, FOX Penny Stocks, Greenbackers, Innovative Marketing, Joe Penny Stocks, Liquid Tycoon, Penny Picks, Penny Stock Pick Alert, Damn Good Penny Picks, PennyPickAlerts, Winning Penny Stock Picks, Pumps and Dumps, RisingPennyStocks, SixFigureStockPicks, Super Hot Penny Stocks, Super Nova Stock Picks, WePickPennyStocks and Penny Stock Pick Report reported previously on Magellan Gold Corporation (MAGE), and today we report on the Company, here at the QualityStocks Daily Newsletter. 

OTCQB-listed, Magellan Gold Corporation intends to establish itself as a major player in the precious metals mining field. It is an exploration stage company and its principal business is the acquisition, exploration, and if warranted, development of mineral resources. Magellan Gold controls projects consisting of the SDA Mill, Mexico; and the El Dorado Gold-Silver Project near the SDA Mill. Magellan Gold is headquartered in Albuquerque, New Mexico.

The Company’s intention is to build up production via the SDA Mill and increase cash flow. Initial production from the El Dorado Gold-Silver Project was planned for 2019, with the ore to be trucked to the SDA Mill for treatment. Other precious metals properties within trucking distance of the SDA Mill have been identified for acquisition. Furthermore, Magellan Gold will leverage opportunities to treat ore on a toll basis for third-party suppliers.

The SDA Processing Plant is a permitted, fully operational flotation mill with a gold-silver leach circuit, situated in Nayarit State, Mexico. The SDA Processing Plant (SDA Mill) is 150 kilometers southeast of the City of Mazatlan near the town of Acaponeta, Nayarit. Magellan Gold purchased the SDA Mill and associated assets, licenses, and agreements in November of 2017.

The El Dorado Gold-Silver Project is planned to be developed as an underground mine to supply feed to the SDA Mill. The El Dorado Gold-Silver Project is near the village of Las Minitas, State of Nayarit, 50 kilometers south of the SDA Processing Plant. The El Dorado Mining Concession consists of a 50-hectare concession valid until March 2030. Magellan holds the concession under an option to purchase.

The Silver District Project is an advanced-stage exploration project in southwest Arizona. In January 2020, the Company announced that it entered into a binding Letter of Intent (LOI) to sell 100 percent of its Silver District project in La Paz County, Arizona, to NV Gold Corporation (TSXV: NVX, US: NVGLF) for cash, NVX shares, and a minimum work commitment over a five-year period.

Recently, Magellan Gold announced that it acquired additional unpatented mining claims in proximity to the unpatented claims comprising the historic Center Star Gold Mine near Elk City, Idaho that was acquired effective July 1, 2020. Magellan has added an additional 320 acres of land to increase its holding to 620 acres of claims along the Center Star gold trend. The new claims are situated in proximity to the earlier acquired claims. They were staked to fortify the land position around Center Star Mine.

The Center Star Mine hosts high grade gold mineralization that was discovered in the early 1900’s, with periodic historic production and development work done under varied ownership through the 1980s. This property is 45 miles from Grangeville, Idaho and near the town of Elk City, Idaho.

Recently, Magellan Gold announced the appointment of Mr. Michael Lavigne as President and Director. In addition to Mr. Lavigne, Mr. Gregory Schifrin was appointed as Director, following Magellan Gold’s acquisition of Clearwater Gold Mining Corporation announced last month. Mr. Lavigne has been involved in the mining industry since 1975. Mr. Schifrin has worked as a geologist and manager for more than 36 years in the mining and mineral exploration industry.

Magellan Gold Corporation (MAGE), closed Tuesday's trading session at $1.15, up 27.7778%, on 8,366 volume with 19 trades. The average volume for the last 3 months is 3,127 and the stock's 52-week low/high is $0.200000002/$1.65499997.

Draganfly, Inc. (DFLYF)

QualityStocks, Shiznit Stocks, RedChip, Penny Stock General and Wealth Insider Alert reported previously on Draganfly, Inc. (DFLYF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Draganfly, Inc. is an award-winning, industry-leading manufacturer within the commercial Unmanned Aerial Vehicle (UAV), Remotely Piloted Aircraft Systems (RPAS). It is the creator of quality, innovative, UVS and software that transforms the way people do business. The Company’s products include quad-copters, fixed wing aircrafts, ground based robots, hand held controllers, and sensors. In addition, products include software used for tracking, live streaming, as well as data collection. OTCQB-listed, Draganfly is headquartered in Saskatoon, Saskatchewan.

Draganfly serves the agriculture, public safety, industrial inspections and mapping and surveying markets. The Company’s custom solutions include Prototyping, Designing, and Engineering.

For Agriculture, Draganfly engages in Enterprise, Production, and Research. It works with its partners to collect high-quality environmental data using a set of sophisticated hardware and sensor technology. Concerning Insurance companies, they use Draganfly hardware, software, and services to quantify the effect of natural disasters and ensure human safety.

Concerning Military & Government, military and government contractors partner with Draganfly to improve personnel and infrastructure safety. For Environmental & Energy, the Company equips energy companies with the hardware and software they require to optimize existing operations, improve safety, and respond after a natural disaster.

Pertaining to Public Safety, Draganfly’s focus is Police, Fire, Hazmat, and Emergency Response. In 2013, the Draganflyer was the first drone to save a human life.

Recently, Draganfly announced that Bulzi, LLC signed a Memorandum Of Understanding (MOU) to use Draganfly’s drones and aerial sensors for their Department of Defense (DoD) Base Security development projects. Bulzi (Newport Beach, California) is a human geospatial intelligence technology and services company. It has been awarded multiple Small Business Innovation Research (SBIR) contracts with US DoD agencies for the purpose of adapting its commercial technologies to enhance US military base security. Draganfly will provide drones with integrated sensors and location perimeter monitoring hardware for Bulzi to use within their security development projects.

Draganfly, Inc. (DFLYF), closed Tuesday's trading session at $2.75, up 26.7281%, on 2,921,922 volume with 4,580 trades. The average volume for the last 3 months is 2,632,471 and the stock's 52-week low/high is $0.257899999/$3.33999991.

Edgewater Wireless Systems, Inc. (KPIFF)

QualityStocks, Today's Stock Tip, StockRunway, StockHideout, Stock Commander, Small Cap Firm, Shiznit Stocks, Penny Stock Titans, Penny Stock General, MegaPennyStocks and BullFreak reported previously on Edgewater Wireless Systems, Inc. (KPIFF), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter. 

Edgewater Wireless Systems, Inc. focuses on Wi-Fi infrastructure with its patented WiFi3™ technology and Next Generation Access Points. The Company commercializes innovative wireless technologies for the service provider market. It is developing considerably improved Wi-Fi network performance across an array of industries and challenging environments with top-notch performance, high flexibility, and consummate security. Established in 1988 by Edgewater Computer Systems, Edgewater Wireless Systems is based in Ottawa, Ontario. The Company lists on the OTC Markets Group’s OTCQB.

Edgewater Wireless Systems has two distinct directions. One is in the Enterprise market, where the Company has validated its unique technology design with players such as Kroger and Mediacom. The second is the massive Consumer (Home) market where Edgewater has made major progress with its alliance with CableLabs.

Edgewater Wireless has a global distribution network and the Company has invested greater than $50 Million in the development of Edgewater Wireless Products. It has sales partners in the United States, the United Kingdom (UK), Brazil, Peru, and Asia.

Edgewater Wireless is patented, standards-compliant Wi-Fi delivering many simultaneous channels of transmit and receive on a single radio in 2.4GHz & 5GHz – called Wi-Fi Spectrum Slicing. MCSR powers its products. Edgewater Wireless WiFi3™ powered access point products enable unique service providers to plan, build, and deploy reliable, high-capacity services (such as VoWiFI) for high-density & data demand in any environment.

Edgewater delivers the highest channel density available on the contemporary market. It uses Edgewater Wireless patented technology, which enables numerous channels on a single chip. Accordingly, aggregate output on a single WiFi3™ powered AP will outperform traditional, single channel APs.

Edgewater Wireless Systems has released a powerful new Wi-Fi Spectrum Slicing Development Kit powered by Edgewater’s MCSR™ chipsets. The Company’s pioneering Dev Kit 2.0 delivers a complete hardware and software package for open source developers to create an ecosystem of apps unlocking the power of Spectrum Slicing to the residential and enterprise Wi-Fi markets.

Mr. Andrew Skafel, Chief Executive Officer of Edgewater Wireless Systems, said, “The latest release of our Dev Kit builds on the success of our earlier release, which was instrumental in securing our first enterprise design-win. We’re excited and proud to offer our latest Dev Kit and expect there is a myriad of applications to be developed.”

Edgewater Wireless Systems, Inc. (KPIFF), closed Tuesday's trading session at $0.145, up 163.6364%, on 3,977,781 volume with 589 trades. The average volume for the last 3 months is 202,415 and the stock's 52-week low/high is $0.009999999/$0.275000005.

First Acceptance Corporation (FACO)

We reported beforehand on First Acceptance Corporation (FACO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Nu-Med Plus, Inc. investigates and develops applications of Nitric Oxide technologies in the medical field. The OTCQB-listed Company formed to explore medical applications of newly developed technologies. Its strategy is to focus on high growth potential markets where there is a clearly defined need recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. A medical device business, the Company is headquartered in Salt Lake City, Utah.

Inhaled Nitric Oxide (INO) is a medically essential gas. It is currently used in Neonate Hypoxia therapy (inadequate oxygen level in newborns), COPD and other pulmonary problems. Nu-Med Plus has the capability to deliver high purity Inhaled Nitric Oxide (INO) to the patient at point of use. INO may have future applications for an assortment of other diseases and medical complications that are now being investigated.

Nu-Med’s markets include neonatal complications, COPD, Tuberculosis, Malaria, and ARDS (a severe lung syndrome with no known cure). The Company’s team has developed a new Nitric Oxide (NO) gas delivery system. This system provides a continuous intra-breath concentration of therapeutic NO to medically supervised patients who are on ventilators in a hospital setting.

Recently, Nu-Med Plus announced it will receive its first clinical unit prototype and commence testing to verify design parameters. The design of the Nu-Med Plus clinical unit is to provide clinicians and care providers a number of key competitive advantages. The small unit fits easily into medical offices, emergency departments, as well as nursing homes. The unit offers a touch screen for ease-of-use and precision single-dose control. The clinical unit uses either a proprietary formula of nitric oxide generation or prefilled nitric oxide canisters.

Mr. Jeff Robins, Chief Executive Officer of Nu-Med Plus, stated, “The clinical unit multiplies the number of markets Nu-Med Plus is able to serve with our technology. The market-leading innovation offers providers and patients new treatment options, in new convenient environments, to address health issues that significantly impact quality of life and cost billions of dollars annually to treat.”

First Acceptance Corporation (FACO), closed Tuesday's trading session at $1.99, up 27.0754%, on 26,523 volume with 69 trades. The average volume for the last 3 months is 12,005 and the stock's 52-week low/high is $0.344999998/$2.69000005.

Nu-Med Plus, Inc. (NUMD)

QualityStocks and SmallCapVoice reported beforehand on Nu-Med Plus, Inc. (NUMD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Nu-Med Plus, Inc. investigates and develops applications of Nitric Oxide technologies in the medical field. The OTCQB-listed Company formed to explore medical applications of newly developed technologies. Its strategy is to focus on high growth potential markets where there is a clearly defined need recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. A medical device business, the Company is headquartered in Salt Lake City, Utah.

Inhaled Nitric Oxide (INO) is a medically essential gas. It is currently used in Neonate Hypoxia therapy (inadequate oxygen level in newborns), COPD and other pulmonary problems. Nu-Med Plus has the capability to deliver high purity Inhaled Nitric Oxide (INO) to the patient at point of use. INO may have future applications for an assortment of other diseases and medical complications that are now being investigated.

Nu-Med’s markets include neonatal complications, COPD, Tuberculosis, Malaria, and ARDS (a severe lung syndrome with no known cure). The Company’s team has developed a new Nitric Oxide (NO) gas delivery system. This system provides a continuous intra-breath concentration of therapeutic NO to medically supervised patients who are on ventilators in a hospital setting.

Recently, Nu-Med Plus announced it will receive its first clinical unit prototype and commence testing to verify design parameters. The design of the Nu-Med Plus clinical unit is to provide clinicians and care providers a number of key competitive advantages. The small unit fits easily into medical offices, emergency departments, as well as nursing homes. The unit offers a touch screen for ease-of-use and precision single-dose control. The clinical unit uses either a proprietary formula of nitric oxide generation or prefilled nitric oxide canisters.

Mr. Jeff Robins, Chief Executive Officer of Nu-Med Plus, stated, “The clinical unit multiplies the number of markets Nu-Med Plus is able to serve with our technology. The market-leading innovation offers providers and patients new treatment options, in new convenient environments, to address health issues that significantly impact quality of life and cost billions of dollars annually to treat.”

Nu-Med Plus, Inc. (NUMD), closed Tuesday's trading session at $0.578, up 40.9756%, on 8,377 volume with 4 trades. The average volume for the last 3 months is 4,154 and the stock's 52-week low/high is $0.400000005/$2.25.

FS KKR Capital Corp. II (FSKR)

MarketBeat and MarketClub Analysis are reporting on FS KKR Capital Corp. II (FSKR), here at the QualityStocks Daily Newsletter.

Shares of FS KKR Capital Corp. II (NYSE:FSKR) traded at a new 52-week high today of $19.66. So far today approximately 529,000 shares have been exchanged, as compared to an average 30-day volume of 524,000 shares.

In the past 52 weeks, FS KKR Capital Corp. II share prices are bracketed by a low of $11.64 and a high of $19.66 and is now at $19.57, 68% above that low price.

FS KKR Capital Corp II is an externally managed, non-diversified, closed-end management investment company. The company's investment objectives are to generate current income along with capital appreciation. It seeks to invest primarily in the senior secured debt and the subordinated debt of private middle market U.S. companies.

FS KKR Capital Corp. II (NYSE:FSKR) defies analysts with a current price ($19.57) 5.3% above its average consensus price target of $18.53.

FS KKR Capital Corp. II (FSKR), closed Tuesday's trading session at $19.38, up 3.2499%, on 1,259,552 volume with 8,332 trades. The average volume for the last 3 months is 596,627 and the stock's 52-week low/high is $11.6400995/$19.6599998.

Hunter Technology (TSX.V: HOC) (OTCQB: HOILF) (WKN: A2QEYH) (FSE: RWPM)

QualityStocks, StocksToBuyNow, NetworkNewsWire, Tip.us and SeriousTraders reported previously on Hunter Technology (HOILF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Hunter Technology (TSX.V: HOC) (OTCQB: HOILF) (WKN: A2QEYH) (FSE: RWPM) has announced a planned April 2021 private release of its OilEx platform as a minimum viable product ("MVP"). The company is planning to market test the platform ahead of the execution of live pilot transactions for selected hydrocarbon producers and purchasers planned for late Q2 2021. The MVP delivery, timed to make the most of the robust solution development progress and plans, will be targeted to independent producers and purchasers in North America. 

The announcement noted that the MVP will provide early users a first glimpse of the OilEx digital marketplace, which consolidates the trading supply and demand and enables transactions with a visual representation of market data utilizing interactive maps to support discovery of attractive transaction opportunities, a secure end-to-end encrypted communication channel between prospective purchasers and sellers supporting, and a robust document storage function. The announcement also noted that Hunter had appointed Dr. Florian M Spiegl to the company's Board of Directors.

"This MVP is a critical step in our product development work,” said Hunter CEO Florian M Spiegl in the press release. “It will allow the detailed validation of the OilEx core product functions to optimize benefits provided to our clients and partners and help realize our core value proposition: connecting independent oil producers, buyers, and traders in a trusted digital marketplace to optimize prices, simplify processes, improve transparency, and support environmental responsibility. We are excited to go through rigorous testing with independent producers in April before we schedule our next major release."

To view the full press release, visit https://ibn.fm/uUF1r

Hunter Technology Corp. is a technology provider developing interactive blockchain platforms to enable the facilitation and supply chain tracking of physical oil transactions throughout the trade cycle, with more favorable economics for producers, access to a fair market for all and a reduced carbon footprint as producers transition towards a more environmentally and ethically responsible ecosystem. Through Oilex.com, Hunter will operate a physical oil marketplace to facilitate the buying and selling of physical oil by independent producers to corporate consumers, traders and sovereign purchasers. Through OilExchange.com, Hunter will offer real-time supply chain management tools for tracking the origin, transhipment and processing of hydrocarbons and the environmental, social and governance (“ESG”) compliance during their life cycle. For more information about the company, please visit www.HunterTechnology.com.

Hunter Technology (HOILF), closed Tuesday's trading session at $1.0525, off by 2.5463%, on 5,807 volume with 33 trades. The average volume for the last 3 months is 33,257 and the stock's 52-week low/high is $0.046867001/$1.34000003.

The QualityStocks Company Corner

Asia Broadband Inc. (OTC: AABB)

The QualityStocks Daily Newsletter would like to spotlight Asia Broadband Inc. (AABB).

Asia Broadband Inc. (OTC: AABB) has announced that its management, including its Board of Directors, recently approved a stock dividend. According to the announcement, the restricted common share dividend will be distributed on the basis of one dividend share for every 50 shares owned to shareholders of record as of April 5, 2021. AABB also released information for shareholders and the investment community regarding communications with its professional service providers. AABB noted that its professional service providers (i.e., auditor, legal firm, token developer, etc.) have received numerous requests for information regarding the company. To view the full press releases, visit http://ibn.fm/oCe8Q and http://ibn.fm/x328E

Asia Broadband Inc. (OTC: AABB) is a resource company focused on the production, supply and sale of precious and base metals, primarily to Asian markets.

The company utilizes its specific geographic expertise, experience and extensive industry contacts to facilitate its innovative distribution process from the production and supply of precious and base metals in Mexico to client sales networks in Asia. This vertically integrated approach to sales transactions differentiates Asia Broadband from its competitors in the mining space.

Development Program in Colima, Mexico

In October 2020, Asia Broadband announced its acquisition of a high potential mineral property in the state of Colima, Mexico. Per the press release, previous geophysics and groundwork have revealed strong indications of significant mineralization in multiple sectors of the property.

The company recently began the construction of exploration and development facilities and infrastructure roads on its Colima property, and plans are underway to extend previous geophysics and groundwork on the property. In January 2021, Asia Broadband announced its allocation of $10 million for the initial development program, with the aim of accelerating operations at the Colima site toward production.

Positioned in a major gold-iron-copper production area, the company’s Colima property is situated approximately 25 kilometers east of the Pena Colorada mine in Minatitlan, Mexico. It is advantageously located, with direct access to main Highway #3, and the property also has an essential natural water supply.

AABB Gold Token

In December 2020, Asia Broadband announced its entry into a definitive development agreement with Core State Holdings Corp., a digital assets and crypto wallet creator, to produce a white label gold-backed cryptocurrency coin. The AABB Gold token is an ERC-20 token being developed on the Ethereum blockchain.

In a February 2021 news release, the company provided a development update on the cryptocurrency token, noting that Core State Holdings Corp. “is continuing to modify the set-up and move through the final stages of testing of the iOS and Android AABB Wallet applications, including the implementation of an application interface to allow users to see the real-time exchange rate of gold that backs the price of the AABB Gold token set at one-tenth of a gram or approximately $5.80 USD.”

Core State Holdings Corp. has also continued to enhance www.AABBGoldToken.com, which the company notes will be the go-to knowledge base for all information concerning the soon-to-be launched AABB Wallet and AABB Gold token.

AABB’s primary goal for the token is to become a worldwide standard of exchange – secured and trusted with gold backing – by expanding circulation and targeting large population and high growth markets globally, including China and East Asia.

Asia Broadband Inc. (AABB), closed Tuesday's trading session at $0.215, off by 10.7884%, on 74,604,952 volume with 7,713 trades. The average volume for the last 3 months is 83,969,691 and the stock's 52-week low/high is $0.0013/$0.658999979.

Recent News

Mohawk Group Holdings Inc. (NASDAQ: MWK)

The QualityStocks Daily Newsletter would like to spotlight Mohawk Group Holdings Inc. (MWK).

Mohawk Group (NASDAQ: MWK), a technology-enabled consumer products company, has scheduled a conference call to report fourth-quarter and year-end financial results. The call is scheduled for Monday, March 8, 2021, at 5 p.m. ET. Investors and other interested parties are invited to participate in the call, which will be accessible by telephone and via the internet. Participants from within the United States can dial (877) 295-1077, and participants from outside the United States should dial (470) 495-9485; the conference ID is 4271887. As an alternative, participants can also watch the broadcast live. In addition, an archived replay of the call will be available in the investors section of the Mohawk corporate website for a short time after the call is concluded. To view the full press release, visit https://ibn.fm/ht4vW

Mohawk Group Holdings Inc. (MWK) is a leading tech-enabled consumer products platform that uses machine learning, natural language processing and data analytics to design, develop, market, and sell products. The company’s proprietary AIMEE(R) platform leverages data and AI to automate the design, development and launch of best-selling consumer products.

Mohawk owns and operates 12 brands and sells consumer products in multiple categories ranging from kitchenware and home appliances to environmental appliances, beauty products and even consumer electronics.

Founded in 2014, Mohawk has offices in the United States, Canada, China and the Philippines. The company is always working to capitalize on the strength of the different cities and time zones in which it operates to ensure continued excellence around the world and achieve its goal of becoming the most consumer-centric product company.

AIMEE(R) Platform

AIMEE(R) (AI Mohawk E-commerce Engine) is Mohawk’s proprietary platform that leverages data and AI to:

  • Identify new market opportunities;
  • Launch new products;
  • Automate marketing variables; and
  • Analyze and optimize company-owned and operated consumer product brands.

The platform’s core functionalities include:

  • Research: Automated research using live market data that tracks exposure and product trends, allowing for the swift discovery of new market and product opportunities;
  • Financials: Places data insights in one place, enabling execution across multiple channels to track new product planning, financial projections, inventory levels, media buying and more;
  • Trading: The result of an algorithmic solution that has been optimized for live decisions to scale sales and built to implement automated marketing strategies with learning through experimentation; and
  • Logistics: Manages logistics to enable faster delivery of products to consumers.

Mohawk’s Business Model

Mohawk’s unique business model is designed to drastically shorten go-to-market time, decreasing the typical 18- to 24-month process to just 6- to 8-months. Using AIMEE(R), Mohawk leverages real-time data-driven opportunities and trend tracking to replace the idea focus group research and development of the standard model.

Marketing time is also reduced between the two models using the AIMEE(R) Trading Engine for data-driven automated marketing and product lifetime management. Through the AIMEE(R) trading engine, the traditional 3-month marketing for a standard go-to-market model is cut to a fraction of the time.

The AIMEE(R) Fulfillment Engine allows for dynamic inventory allocation, fulfillment selection, cost optimization, a third-party logistics network and a 2-day shipping period across almost all of the United States. The standard business model doesn’t support direct distribution or an FBA (fulfilled by Amazon) structure.

Opportunities for Growth and Profitability

Mohawk’s plan to drive growth and profitability in the market includes:

  1. The continued optimization of product economics by lowering manufacturing and logistical costs through an increase in purchasing power
  2. The pursuit of higher-value products with larger target markets
  3. Opportunistically adding new products and categories through acquisitions
  4. Expansion into the international and new domestic e-commerce marketplaces
  5. Monetization of its proprietary AIMEE(R) platform by providing access to third-party brands

Mohawk’s long-term goal is to increase its profit margin from 14% in 2020 to 18-20%, using higher average selling prices and lower fulfillment costs as primary drivers. Due to its technology and platform effect, Mohawk’s corporate overhead is expected to increase at a slower pace than sales. Its fixed operating costs long-term target goal is 5%, which follows the current trend (2019 – 19%, 2020 – 13%). It aims for an adjusted EBITDA of 13-15%.

Management Team

Yaniv Sarig has been Mohawk’s President and Chief Executive Officer since September 2018. He is also a co-founder of Mohawk Group Inc. Mr. Sarig has served as the President and Chief Executive Officer of Mohawk Group Inc. since June 2014. Before his role at Mohawk, he led the Financial Services Engineering department at Coverity, a software startup providing code and security solutions to top financial institutions and hedge funds in New York to include the New York Stock Exchange, Nasdaq, JPMorgan Chase and Barclays. Before his Coverity role, Mr. Sarig held lead technical roles at Bloomberg and EPIQ Systems Inc. (NASDAQ: EPIQ). He holds a Bachelor of Science from Touro College. He is fluent in English, French, Hebrew and C++.

Fabrice Hamaide has been the Chief Financial Officer of Mohawk since September 2018. He has also retained the position of Chief Financial Officer for Mohawk Group Inc. since July 2017. Before Mohawk, Mr. Hamaide held numerous financial, CFO and presidential roles in various technological and consumer product companies across Europe and the United States, including Piksel Inc., Atari, Parrot and Logitech. Mr. Hamaide holds an impressive set of credentials, including an MBA from Columbia Business School, an MS in Information Systems Design from Sorbonne University, and a BS in Applied Mathematics from Jussieu University.

Mihal Chaouat-Fix has been the Chief Product Officer for Mohawk since September 2018. Prior to taking this role within the company, she was the Chief Operating Officer, handling the day-to-day leadership and operational management of Mohawk. Before joining Mohawk, Ms. Chaouat-Fix worked in various roles at Gottex Models Ltd. At this international fashion swimwear firm, her focus on marketing, operations and manufacturing saw supply chain and distribution of 12 million units per year to over 40 countries worldwide.

Tomer Pascal has been the Chief Revenue Officer for Mohawk since 2018. He has also served as the Chief Revenue Officer for Mohawk Group Inc. since 2017. Before he joined the Mohawk team, he was the Chief Executive Officer and co-founder of OMG Studios. Throughout his career, Mr. Pascal has held many different co-founder and general management roles, focusing on companies’ marketing and revenue growth in the media and technology industries.

Roi Zahut has held the role of Chief Technology Officer for Mohawk since 2019. Before Mohawk, he served in numerous roles, including CTO of the Advanced Analytics global consulting team at IBM and architect of IBM Metropulse. While in Israel, Mr. Zahut held several senior technical, business and data science roles in startups and consulting to include IBM Israel, Brainbow Ltd. and Matrix IT Ltd. He holds an MSc in Neuroscience with distinction from Bar Ilan University.

Mohawk Group Holdings Inc. (MWK), closed Tuesday's trading session at $43.99, up 0.091013%, on 541,039 volume with 5,811 trades. The average volume for the last 3 months is 861,679 and the stock's 52-week low/high is $1.41999995/$48.9900016.

Recent News

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

Energy Fuels (NYSE American: UUUU) (TSX: EFR) has partnered with Neo Performance Materials (TSX: NEO) to unveil a new rare earth production initiative spanning both North American and European critical material supply chains. The separated rare earth products produced in Europe from U.S.-sourced feedstock should strengthen and diversify the U.S. and European rare earth supply chains. As outlined in the announcement, the initiative will produce value-added rare earth products from natural monazite sands processed by Energy Fuels in the Southeastern United States. To view the full press release, visit https://ibn.fm/PEjwb

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR),based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

  • White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
  • Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
  • Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon‐free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

  • Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
  • Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
  • Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

  • La Sal Complex (Utah)
  • Whirlwind Mine (Colorado/Utah)
  • Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

Energy Fuels Inc. (UUUU), closed Tuesday's trading session at $6.19, up 19.2678%, on 10,898,922 volume with 42,290 trades. The average volume for the last 3 months is 5,174,601 and the stock's 52-week low/high is $0.779999971/$6.4499998.

Recent News

Uranium Energy Corp. (NYSE American: UEC)

The QualityStocks Daily Newsletter would like to spotlight Uranium Energy Corp. (NYSE American: UEC).

Uranium Energy (NYSE American: UEC), a Corpus Christi, Texas-based uranium mining and exploration company, today announced that Spencer Abraham, UEC's chairman and former United States Secretary of Energy, will be speaking tomorrow, March 3, 2021, in a virtual fireside chat at the BMO Global Metals and Mining Conference. Interested parties can access Abraham's live fireside chat at 5:45 p.m. ET through the registration link at https://ibn.fm/tXw7o. In addition, a replay of the session will be made available on the BMO conference web app after the event and will be accessible to registered attendees. To view the full press release, visit https://ibn.fm/LS18P. Also today, the company was highlighted in a publication from PennyStocks.com, looking at the uranium energy sector.

Uranium Energy Corp. (NYSE American: UEC) is a U.S.-based uranium mining and exploration company that controls one of the country’s largest historical uranium exploration and development databases. Founded in 2003, UEC is headquartered in Corpus Christi, Texas. Properties acquired by the company are primarily located within the United States, including Texas, New Mexico, Colorado, Arizona and Wyoming.

Through the use of historical exploration data, UEC has been able to target and acquire properties that have already been subject to exploration and development by senior energy firms in the past.

UEC is well-financed to aggressively pursue key developmental targets. The company is also well-positioned to capitalize on rising global demand for more uranium and more carbon-free energy, and it uses technology that contributes to a cleaner environment.

In-Situ Recovery (ISR) Technology

In-situ recovery (ISR) technology is a low-cost and environmentally friendly mining technology utilized by UEC at its fully licensed projects, including Palangana, Burke Hollow, Goliad and Reno Creek.

ISR technology involves the circulation of naturally occurring and benign groundwater through a uranium ore body. This natural water (that is unfit for any other use) plus oxygen is pumped into injection wells through the uranium ore body, where the uranium in the host sandstone is oxidized and solubilized. The uranium bearing groundwater continues to flow through the sandstone to the extraction wells, where it is pumped to the surface. This water proceeds to an ion exchange unit (like a big water-softener) for uranium removal, then is pumped back to the wellfield and again re-circulated through the ore body. This recirculation of the same groundwater continues over and over, until the uranium in the sandstone is depleted.

In the ion exchange process, the extracted uranium in solution is concentrated on resin beads for transport to the Hobson Processing Facility. There, the uranium then undergoes several simple processing steps before being dried and packaged as “yellowcake” that will be transported to a conversion facility, where its sold to UEC customers.

Hobson Processing Plant

Hobson is the centerpiece in UEC’s hub and spoke production strategy, with low-cost satellite ISR operations all within relatively short trucking distance. The plant is fully licensed and currently on standby with an annual production capacity of 2 million pounds of U3O8. The spokes of the UEC strategy include the Palangana, Burke Hollow, Goliad, Salvo and Longhorn ISR projects. With an improvement in uranium prices that justify production, UEC plans to restart the plant with uranium loaded resins originating first from Palangana and then followed by Burke Hollow. UEC has applied for a license amendment with the Texas Commission on Environmental Quality to increase the Hobson facility’s production capacity to 4 million pounds per year.

Current Projects

Uranium Energy’s current project portfolio includes:

  • Texas – Hobson Processing Plant, Palangana Mine, Goliad, Burke Hollow, Salvo and Longhorn
  • Wyoming – Reno Creek
  • Paraguay – Oviedo, Yuty and Alto Paraná
  • New Mexico – Dalton Pass and C de Baca
  • Colorado – Long Park and Slick Rock
  • Arizona – Anderson, Los Cuatros and Workman Creek
  • Canada – Diabase

Uranium Market Outlook

The long-term fundamentals underlying the market continue to strengthen. Currently, UEC sees an annual gap of about 40 million pounds between uranium production and utility requirements. Current forecasts show this structural deficit persisting at least through 2026 and then expanding further to almost 70 million pounds per year by 2030. While secondary supplies have been filling the void, those supplies are not a sustainable long term supply source. There are different estimates on timing, but it is clear secondary supply (that includes inventory drawdowns) will be insufficient to fill the projected gap between supply and demand, and new production will be required. As this transition evolves, the market will become more production cost driven as opposed to inventory driven.

Higher priced contracts that have supported high production costs are continuing to roll out of producer and utility supply portfolios. These higher priced contracts are not replaceable, with current market prices below production costs for the vast majority of western producers. This will likely continue the trend of production cuts and deferrals until prices rise sufficiently to sustain long-term mining operations.

In the U.S., some of the foreign State-Owned Enterprise (“SOE”) supply that has been flooding the market will be reduced. Last year, the U.S. Department of Commerce negotiated an amendment to the Agreement Suspending the Antidumping Investigation on Uranium from the Russian Federation that reduces America’s dependence on Russian natural uranium concentrates by up to 75% from prior levels. Due to a prolonged weak pricing environment from an influx of price insensitive supply from SOEs, U.S. production is effectively zero, less than 1% of U.S. requirements.

On the demand side of the equation, further upside market pressure also appears likely to evolve as utilities return to a longer-term contracting cycle to replace expiring contracts. Over the longer term, there continues to be underlying and increasing demand building, as the globe continues a push toward carbon-free energy goals. Those goals will require the 24/7, base load, clean energy that nuclear power provides as part of the overall supply mix. A good example of that policy messaging came from Japan’s energy minister, who recently said he considers nuclear energy “indispensable” if the country is to meet its net-zero carbon emission goals.

Exacerbating the overall supply picture, lead times for new production typically range from seven to 10 years or longer. The market appears to be within the time frames required for investment to bring new supply online to meet those lead times. However, prices are not yet at levels that incentivize future production, increasing the probability of the potential for less supply than the market is currently pricing in. All things considered, UEC believes the supply and demand fundamentals should continue to exert upward pressure on uranium prices.

Management Team

Spencer Abraham is Chairman of the Board for UEC. He served as the 10th U.S. Secretary of Energy from 2001 to 2005. He is an honors graduate of Michigan State University and Harvard Law School, and he was a law professor at the Thomas M. Cooley School of Law. He was elected chairman of the Michigan Republican Party in 1983 and later served as deputy chief of staff in the office of the vice president and as co-chairman of the National Republican Congressional Committee. In 1994, Mr. Abraham was elected to the United States Senate from Michigan and has also served as a director of Occidental Petroleum and as the non-executive chairman of AREVA’s U.S. board.

Amir Adnani is the Chief Executive Officer, President and Director of Uranium Energy. He advanced the company from concept to United States production within its first five years. Mr. Adnani has developed an extensive pipeline of low-cost and near-term production projects. He is the founder and Chairman of GoldMining Inc. (TSX: GOLD) (OTCQX: GLDLF), a gold-resources acquisition and development firm. He is also the Chairman of Uranium Royalty Corp. (TSX.V: URC). Mr. Adnani holds a Bachelor of Science from the University of British Columbia. He is a director of the University’s Alumni Association.

Scott Melbye is the company’s Executive Vice President. He is a 36-year veteran of the nuclear energy industry and has held numerous leadership positions in major uranium mining firms. He is also the current President, CEO and Director of Uranium Royalty Corp. He is an advisor to the Nuclear Energy Program at the Colorado School of Mines. Prior to his work at Uranium Participation Corp., Mr. Melbye worked for Cameco Inc. for 22 years. He received a Bachelor of Science in Business Administration with a specialization in International Business from Arizona State University in 1984.

Bruce Nicholson is the company’s Vice President of Corporate Development. He has spent 16 years as a specialist in the industry, serving major United States and European banks, broker-dealers and investment funds. Mr. Nicholson is a member of the Minerals Economics and Management Society, Minerals Industry Analyst Group, and the New York Society of Securities Analysts. He graduated with an MBA in Finance from Rutgers University in 1995 and is a CFA charter holder.

Uranium Energy Corp. (UEC), closed Tuesday's trading session at $2.38, up 12.2642%, on 7,611,381 volume with 19,590 trades. The average volume for the last 3 months is 4,729,727 and the stock's 52-week low/high is $0.349999994/$2.55999994.

Recent News

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT)

The QualityStocks Daily Newsletter would like to spotlight XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT).

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) was featured today in a publication from BioMedWire, examining how the coronavirus pandemic has affected many industries and economies worldwide, in addition to causing the deaths of more than 500,000 people in America and 2.3-plus million people globally. Understanding how seasonal temperature changes affect virus transmission is crucial in decreasing the spread of the virus in the future.

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. This includes products that are being readied for commercialization within the coming weeks, such as a rapid COVID-19 PCR test kit that reduces turnaround times to less than 30 minutes.

The company has research and development operations in North America and Europe and an operational focus in Germany. Its regulatory approval and commercialization focus is currently on products for the European market.

XPhyto was founded in 2017 and is headquartered in Vancouver, British Columbia.

Business Strategy & Milestones for 2021

On January 18, 2021, XPhyto issued a news release detailing its business strategy for the coming year. The company noted that it is “on the cusp of transformational change as product development programs advance from the laboratory to the clinic.” In addition to continuing to leverage its scientific expertise and operations in North America and Europe for product development and optimization, XPhyto intends to pursue growth through the commercialization of existing products and adherence to a focused investment strategy targeting impact-driven innovation with “the potential for extreme value creation.”

In particular, XPhyto is well positioned to execute on opportunities across its current business divisions, including:

  • Commercialization of infectious disease diagnostics
  • Clinical validation of transdermal and sublingual drug formulations
  • Continued investment and development in psychedelic medicine

“2020 was a very productive year for XPhyto. We made significant progress in all areas of our business,” Hugh Rogers, CEO & Director of XPhyto, stated in the update. “We have ambitious milestones for 2021 with multiple product launches on the horizon, multiple clinical drug programs underway, and an aggressive commitment to psychedelic medicine. I am extremely confident that our team can execute on the company’s business plan for 2021.”

Infectious Disease Diagnostics

XPhyto’s lead diagnostic product, secured through an exclusive global commercialization agreement with 3a-diagnostics GmbH (“3a”), is a rapid and highly portable PCR diagnostic test. Notably, PCR testing “has emerged as the only internationally recognized standard for COVID-19 testing” and is expected to play a key role in facilitating the recovery of the domestic and international travel industries, among others.

Successful validation of the PCR system was achieved in Q4 2020, and XPhyto has expressed confidence that it will achieve European commercial (CE-IVD) approval in Q1 2021. In preparation for this milestone and an anticipated Q1 product launch, the company is currently in discussion with manufacturing and distribution partners in Europe and the Middle East.

In addition to COVID-19 products, XPhyto and partner 3a are developing and commercializing a portfolio of low-cost oral biosensors. The company’s lead biosensor product is an oral health screening test for the detection of peri-implantitis for which XPhyto is targeting a late 2021 European commercial approval.

XPhyto does not make any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic.

Drug Formulation & Delivery

In 2020, XPhyto’s German subsidiary, Vektor Pharma TF GmbH (“Vektor”), reported significant advancement in four therapeutic programs targeting neurological indications with significant market demand. Vektor also successfully developed a sublingual drug formulation on contract for a major generic drug manufacturer and distributor.

XPhyto will look to build on this progress in 2021, with plans to complete human pilot studies evaluating its four lead therapeutic products:

  • Rotigotine transdermal patch for Parkinson’s disease
  • CBD oral/sublingual strip for treatment resistant epilepsy
  • THC oral/sublingual strip for anorexia/nausea
  • CBD:THC (1:1) oral/sublingual strip for multiple sclerosis associated spasticity

Per its 2021 business update, the company is currently in “ongoing discussions with multiple potential commercial partners, licensors and distributors and will be reviewing monetization opportunities on a continued basis.”

Psychedelic Medicine

Psychedelic compounds are a highly promising new class of active pharmaceutical ingredient (“API”) demonstrating strong potential for a variety of mental health conditions. XPhyto is positioned to capitalize on this promise through two strategic initiatives:

  • An agreement for the development of industrial scale biotechnology processes for the production of psilocybin
  • An agreement for R&D related to multiple psychedelic compounds, including psilocybin, mescaline, LSD, MDMA and DMT, among others

XPhyto intends to advance and expand its programs focused on the industrial scale production of psychedelic API in 2021. The company also plans to launch new programs for the development of psychedelic drug formulations, with a focus on sublingual and transdermal therapeutics and the integration of these products into established clinical programs relating to mental health indications.

Management Team

Hugh Rogers is the CEO and Director of XPhyto Therapeutics Corp. He is an entrepreneur and lawyer with private and public start-up company experience in various industries and operational roles. His recent advisory work has focused on public listings and corporate restructuring. This restructuring has occurred in the life science (cell therapy and medical device) and natural resources (natural gas co-gen and conventional oil) industries. Mr. Rogers holds a bachelor’s degree in Cellular Biology and Genetics and a law degree. He is a member in good standing of the Law Society of British Colombia.

Christopher Ross is the CFO of XPhyto. He is a professional accountant with broad financial experience across numerous industries, including forestry, distribution, construction, mining and multi-family real estate. He has provided advisory services to private and public companies in the areas of financial accounting, strategic analysis, audit and taxation. Mr. Ross holds a bachelor’s degree in commerce. He is a member in good standing with the Chartered Professional Accountants Association of British Columbia.

Wolfgang Probst serves as Director of XPhyto and Managing Director of BUNKER Pflanzenextrakte GmbH. He is a seasoned management and financial consultant based in Bavaria, Germany. He has consulting experience as branch head working with private clients and corporations of high net worth. In 2017, Mr. Probst assumed the CFO role of BUNKER and continues to play a key role in its operational and financial development.

Professor Dr. Raimar Löbenberg serves as Director of XPhyto. He holds a Bachelor of Science in pharmacy from Johannes Gutenberg-University and a Ph.D. in pharmaceutics from the Johann Wolfgang Goethe-University. He is the co-founder of RS Therapeutics Inc., which concentrates on foam-based topical drug delivery systems.

Professor Dr. Thomas Beckert is the Founder and Managing Director of Vektor Pharma TF GmbH. His expertise includes the formulation and machine development of transdermal therapeutic systems and ODFs. Professor Beckert holds a Bachelor of Science in pharmacy from the University of Freiburg and a Ph.D. in pharmacy and economics from the University of Tubingen.

XPhyto Therapeutics Corp. (OTCQB: XPHYF), closed Tuesday's trading session at $2.255, up 2.50%, on 30,200 volume with 99 trades. The average volume for the last 3 months is 68,506 and the stock's 52-week low/high is $1.3125/$3.0999999.

Recent News

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Predictive Oncology (NASDAQ: POAI) was highlighted today by PennyStocks.com. With the approval of a new vaccine and a bullish response from investors, penny stocks are showing higher volume across the board. While heightened volume may not seem like a big deal, it indicates several factors about individual security. For one, higher than average volume means more investor attention.

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

  • A database of clinically validated historical and outcome data from patient tumors
  • An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
  • A “smart” patient-derived tumor profiling platform
  • An in-house bioinformatics artificial intelligence (AI) platform
  • A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
  • An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Tuesday's trading session at $1.76, up 10.00%, on 5,447,545 volume with 11,910 trades. The average volume for the last 3 months is 4,268,744 and the stock's 52-week low/high is $0.629999995/$4.42000007.

Recent News

Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF)

The QualityStocks Daily Newsletter would like to spotlight Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF).

Clean Power Capital (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF), an investment company, has announced that one of its investee companies, PowerTap Hydrogen Fueling Corp., has partnered with Carbonomics to obtain Low Carbon Fuel Standard (“LCFS”) certification of certain hydrogen fueling stations in California, a global leader in establishing and maintaining a robust emissions credits market. To view the full press release, visit http://ibn.fm/wOqvy. Also today, the company was featured in a publication from Green Car Stocks, examining how last year, US-based EV startup Aptera caused waves when it unveiled its prototype for a lightweight, super-efficient electric vehicle (“EV”) with a range of up to 1,000 miles. After folding back a bit, Aptera relaunched in 2020, revealing plans for a three-wheeled electric vehicle it claimed would never need charging, thanks to a solar array. Two months later, the San Diego, California, firm has raised $4 million in funding and received more than 7,000 reservations.

Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) is an investment holding company that focuses on investing in and providing early-stage financing to both public and private businesses. Since its original listing with the Canadian Stock Exchange (“CSE”) on January 23, 2019, the company has made investments in a number of different businesses in a variety of industries, including the energy and cannabis sectors. As per the company’s investment policy, its primary goal is to identify and capitalize on high-return investment opportunities presenting the ability to achieve capital appreciation and liquidity.

Clean Power Capital continues to be opportunistic in evaluating prospects across the renewable energy, bio-medical, pharmaceutical and naturopathic sectors, both as an investor and as an operator. The company’s main focus at the moment is to identify such opportunities in the renewable energy industry, including wind, solar and geothermal power and hydrogen and fuel cell technologies, as well as in the biomedical, pharmaceutical and naturopathic sectors, which may include medical or recreational cannabis.

Clean Power Capital currently has 10 investments in a variety of sectors and successfully held nearly C$120 million in investments during the past fiscal year (https://ibn.fm/8oktZ). It returned capital to its shareholders through the distribution of its interest in AgraFlora Organics International Inc. in May 2020 (https://ibn.fm/FRAvq).

Headquartered in Vancouver, British Columbia, Clean Power Capital was formerly named Organic Flower Investments Group Inc. As of November 10, 2020, the company officially changed its name to Clean Power Capital and started trading on the CSE under new ticker symbol ‘MOVE’.

PowerTap Acquisition, Hydrogen Fueling Infrastructure Collaboration

In alignment with its updated investment policy, a reconstituted investment committee and a revised strategy to reflect its focus on the renewable energy market, Clean Power Capital recently completed the acquisition of a 90 percent equity interest in California-based PowerTap Hydrogen Fueling Corp.

Leveraging an impressive portfolio of IP and advanced deployed technologies developed over two decades via substantial investments and partnerships, PowerTap is working on building and expanding a hydrogen filling station network, initially across North America. The company believes that its platform has a significant advantage over other hydrogen fueling stations, because it has a smaller physical footprint and further has the capacity to produce hydrogen fuel on site. As most other hydrogen fueling stations buy hydrogen for storage at higher costs, PowerTap’s model is believed to be exponentially more cost-effective and expandable.

Clean Power Capital’s investment and acquisition will allow PowerTap to step up its efforts and begin work on the hydrogen fueling station network in stages, starting with engineering and design, ongoing development of PowerTap’s third generation product and, finally, licensing & permitting and site preparation. Development is expected to begin in Q4 2021 with engineering and design. Overall, the initial portion of the project is expected to cost $17 million, with Clean Power Capital and PowerTap planning to secure government financing and credit, as well as equity, debt and convertible debt offerings, to fund the infrastructure’s development.

PowerTap technology is already deployed across multiple hydrogen fueling stations in public and private enterprises spanning California, Maryland, Massachusetts and Texas. The company plans to deploy its hydrogen fueling infrastructure at existing truck stops and gas stations across the country, beginning with up to 1,000 stations within the next three to five years. At the moment, there are roughly 70 active hydrogen fueling stations operational and available to consumers in the United States.

Hydrogen Industry Outlook

The project is expected to bring significant opportunities for PowerTap and Clean Power Capital on the fast-growing hydrogen market, driven by a worldwide focus on clean energies and environmentally friendly fueling solutions for the transportation industry.

Hydrogen-powered vehicles come with tremendous advantages over gas, diesel and even electric vehicles in terms of cost per mile, fueling time and driving range, as well as boasting significantly lower emissions. Well-established vehicle manufacturers such as Hyundai, Toyota, Daimler and Volvo are already including hydrogen-powered cars in their product lineups, and Nikola Motors has announced plans to manufacture hydrogen electric long-haul vehicles.

“As an experienced developer of technology in an important area that is finally having its time as a green but also economically compelling energy option, PowerTap is intent on becoming a leading part of the multi-billion dollar hydrogen fueling space,” PowerTap CEO Raghu Kilambi explained in a news release on October 28, 2020 (https://ibn.fm/oaXem).

A recent industry report developed by a coalition of major oil and gas, power, automotive, fuel cell and hydrogen companies indicates that the sector is expected to grow to $140 billion a year in revenue by 2030, creating 700,000 jobs in the U.S. alone (https://ibn.fm/UMI5q). According to Fuel Cell and Hydrogen Energy Association President Morry Markowitz, the sector could expand to $750 billion a year in revenue and 3.4 million jobs by 2050.

The U.S. is already engaged in the hydrogen economy, having more than half of the global number of fuel cell vehicles and investing hundreds of millions of dollars a year, but the country can greatly expand its global energy leadership by scaling up operations in the hydrogen economy, per the industry report.

With the upcoming change in administration in January 2021, the U.S. is expected to renew its commitment to clean energy. Moreover, the U.S. federal government is expected to invest significantly in clean energy and related infrastructure, including hydrogen, according to PowerTap.

“As the U.S. federal government has previously invested in the PowerTap technology, we are optimistic that we will have a seat at the table when USA clean energy/hydrogen infrastructure spending initiatives are designed,” Kilambi added.

Management Team

Joel Dumaresq is the CEO and interim CFO of Clean Power Capital. He is a proven executive with extensive operational and senior management experience in mining, energy and alternative energy, as well as the cannabis and hemp space. Dumaresq began his career in the corporate finance space, having spent 12 years with RBC Dominion Securities. He brings 30 years of experience in the financial sector to the company, has been instrumental in raising over $250 million in venture capital finance, and he has personally managed a number of successful public listings.

Brendan Purdy serves as a director of Clean Power Capital. An experienced businessperson who has led five different companies, Purdy brings years of experience in different industries, including cannabis, blockchain and data security, gaming, mining and energy, and finance and law. He received a graduate degree from the University of Ottawa and an undergraduate degree from the University of Western Ontario.

Theo van der Linde serves as a director of Clean Power Capital. He is a Chartered Accountant with over 20 years extensive experience in finance, reporting, regulatory requirements, public company administration, equity markets and financing of publicly traded companies. He has served as a CFO & Director for a number of TSX Venture Exchange- and Canadian Securities Exchange-listed companies over the past several years. His industry experience spans the financial services, manufacturing, oil & gas, mining and retail industries. More recently, van der Linde has been involved with future use trends of natural resources, as well as other disruptive technologies.

Raghu Kilambi is the CEO and CFO of PowerTap Hydrogen. He is a seasoned investor and entrepreneur with over 25 years of global business experience in public and private investments, building businesses and creating shareholder value. He has raised over $1 billion of equity and debt capital for private and public companies and been involved in many M&A acquisitions and exits.

Clean Power Capital Corp. (OTC: MOTNF), closed Tuesday's trading session at $1.61, up 2.5478%, on 242,964 volume with 225 trades. The average volume for the last 3 months is 218,428 and the stock's 52-week low/high is $0.0315/$2.78999996.

Recent News

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services Global Corporation (OTCQB: SHRG), formerly Sharing Services Inc., today announced its plan to launch a new travel company, a direct selling division focused on providing exclusive benefits and first-class discount travel opportunities to its brand partners and customers as one of its Hapi Brands subsidiaries. According to the update, the new travel company is designed to be an exclusive travel club that will be fully unveiled and launched in 2021, with a focus on providing a “Passport to Happiness” theme to its members and customers. To view the full press release, visit https://ibn.fm/tiWde

Sharing Services Global Corporation (SHRG), formerly Sharing Services Inc., is a diversified company dedicated to maximizing shareholder value, operating through two primary subsidiaries: Elepreneurs Holdings, a direct-selling company, and Elevacity Holdings, a products company. Headquartered in Plano, Texas, SHRG markets and distributes Elevate-branded health and wellness products through an independent sales force of distributors called Elepreneurs.

Proprietary Products

SHRG’s current exclusive Elevate product offerings are marketed under the Elevacity brand, so named to signify the company’s commitment to elevating lives.

The Elevate health and wellness product line consists of nutraceutical products that SHRG refers to as D.O.S.E., which stands for dopamine, oxytocin, serotonin and endorphins – all of which are key hormones proven to promote happiness and well-being.

Elevacity brand products are carefully formulated, chosen and designed to support a single objective: elevate the happiness and well-being of the consumer.

Global Network of Elepreneurs

Elevacity products are shared and sold by a growing international network of home-based entrepreneurs, called Elepreneurs, operated by Elepreneurs Holdings. This SHRG subsidiary provides basic and advanced programs for both new and experienced entrepreneurs who are focusing on their direct-sales careers.

SHRG’s high-performing independent sales force follows the company’s Blue Ocean selling strategy, an approach that encourages individuals to seek new markets, lead, and to “stop competing and start creating.” The Blue Ocean strategy is based on the book, “Blue Ocean Strategy,” written by Professor Renée Mauborgne, who notes that “the lesson here is that the best defense is offense, and the best offense… is to make a blue ocean shift and create your own blue ocean.”

Following this selling strategy, SHRG’s Elepreneurs are taught that, rather than competing directly in a competitive, direct-selling market, they should focus on making competitors irrelevant and succeeding in an uncontested marketplace.

In addition, SHRG’s Elepreneurs use the interactive, video-based VERB sales-marketing platform developed by Verb Technology Company Inc. The app utilizes proprietary interactive video data collection and analysis technology and provides next-generation customer relationship management, lead generation, and video marketing software applications.

Continued Momentum as Industry Leader

These selling strategies have resulted in sharp and consistent revenue gains. In the company’s 10-Q filed with the SEC for the three months ended Oct. 31, 2019, SHRG reported sales of $38.8 million for fiscal Q2 2019, an increase of 116% over sales of $17.9 million reported for the comparable quarter of 2018. Consolidated gross profit jumped by $16.2 million to $27.4 million for the same period compared to Q2 2018.

SHRG’s consolidated operating earnings were $3.9 million in the fiscal quarter ended Oct. 31, 2019, compared to $866,802 for the comparable period the prior year. Consolidated gross margin also grew 70.9% for the three months ended Oct. 31, 2019, compared to 62.2% the prior year.

These numbers are continuing a trend established over the past two years. In fiscal Q1 2019, SHRG achieved revenues of $35.4 million, more than double that of the comparable period in 2018. Even earlier, the company reported sales of $85.9 million for fiscal year ended April 30, 2019. This represents a nine-fold increase, or $77.5 million jump, over the company’s revenues of $8.4 million the prior year.

These numbers bring SHRG’s sales revenues since December 2017 — when the company’s Elevate product line was released — to an impressive cumulative total of $169 million.

Preparing for Success

SHRG is well prepared to continue and accommodate for this growth. The company recently expanded its corporate footprint by moving to a 10,000-square-foot facility in Plano, Texas, that offers ample room to expand as the company grows and flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

In addition, the company has a seasoned, expert leadership team in place, led by John “JT” Thatch. Thatch was appointed president and CEO of SHRG in March 2018, bringing to the company his expertise obtained from successfully starting, owning and operating several businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist SHRG as the company aims to expand and increase revenues.

Contact
469.304.9400 x 201
Info@SHRGinc.com
http://www.SHRGinc.com

Sharing Services Global Corporation (SHRG), closed Tuesday's trading session at $0.42, up 12.8714%, on 1,551,586 volume with 444 trades. The average volume for the last 3 months is 227,922 and the stock's 52-week low/high is $0.027/$0.730000019.

Recent News

Grapefruit USA Inc. (OTCQB: GPFT)

The QualityStocks Daily Newsletter would like to spotlight Grapefruit USA Inc. (OTCQB: GPFT).

Grapefruit USA Inc. (OTCQB: GPFT) was featured today in the 420 with CNW by CannabisNewsWire. Virginia’s Legislature recently passed a measure that would legalize adult-use cannabis in the state. The Senate passed the initiative in a 20–19 vote while the House approved it in a 48–43 vote, making Virginia the only state in the Old South to allow legalization. It should be noted that not one Republican in either chamber voted for the measure.

Grapefruit USA Inc. (OTCQB: GPFT) is a Delaware corporation that is a fully licensed premier cannabis manufacturer and distributor in the legal cannabis marketplace with its own patented and branded line of products.

The company manufactures its patented product line and distributes it, along with other cannabis products, to all properly licensed cannabis product businesses.

Grapefruit is the only cannabis company that has harnessed cutting edge science and technology to bring patented, truly disruptive products to the medicinal and recreational cannabis marketplace, fundamentally changing the way individuals use THC, CBDs and hemp-derived CBDs and capitalizing on the rise in demand for these unique products.

Headquartered in Los Angeles, California, the company has held licensing in the state for manufacturing and distributing cannabis since 2018. Grapefruit currently owns and operates a California-licensed cannabis extraction laboratory and a licensed wholesale distribution facility in the Coachillin’ Canna-Business Park near Palm Springs, California. Grapefruit is managed by a team of experts who possess the experience, skills and resources required to succeed in the competitive cannabis marketplace.

Hourglass™ Topical Delivery Cream

Grapefruit’s patented Hourglass™ topical delivery cream has solved the previously insurmountable difficulties of efficient skin absorption of THC and other cannabinoids.

Hourglass™ allows users to experience a sustained and holistic delivery of THC/cannabinoids providing “the entourage effect” following initial application to the skin. Additional applications may be made confidently and discreetly at the user’s discretion. There simply is no other product on the planet which successfully utilizes a patented time release THC and CBD delivery mechanism to deliver the holistic benefits of cannabis to those who need it.*

Hourglass™ is a unique, highly concentrated full spectrum time-release topical delivery cream that releases a holistic amount of THC, along with a wide range of cannabinoids (or just CBD), over a four- to eight-hour period.* The formula then comes off through the natural sloughing process of dead skin cells. Hourglass provides many holistic benefits, all of which promote health and wellness as it’s number one goal.

Hourglass™ provides users with an entourage effect of THC plus a wide range of cannabinoids, including CBD, Cannabinol (CBN), Cannabigerol (CBG), Delta-8, Tetrahydrocannabivarin (THCV), and Cannabielsoin (CBE) in a Patchless Patch™ system that is novel and proprietary to the company.

Hourglass™ Topical Delivery Cream has fundamentally changed the way individuals use THC and cannabinoids to obtain their holistic benefits.* As a result, smoking cannabis or hemp flowers and orally consuming edibles, which are metabolized in the gut and liver resulting in uneven reactions, are no longer the exclusive ways to receive both the medicinal and recreational benefits of THC/cannabinoids.* Now for the first time in history, there is an effective, easy to use third choice – Hourglass™ by Grapefruit.

*This product is not regulated by the FDA and is not intended to cure, mitigate, treat or prevent disease.

Grapefruit Cannabis Services

Grapefruit distributes cannabis flower and cannabis products, including its own proprietary products, as well as a wide range of services, to other properly licensed cannabis product businesses. These products and services include:

  • Distribution – As a premier licensed distributor, Grapefruit handles the distribution of all-things cannabis throughout California, specializing in bulk AAA exotic indoor flowers sourced from farms located in the state. The wholesale distribution arm facilitates flowers, fresh and dry frozen, and oil transactions in bulk wholesale form. Its wholesale distribution arm distributes its patented Hourglass™ topical delivery cream.
  • Manufacturing – The company owns and operates a fully licensed and compliant ethanol extraction lab that produces a high-quality distillate. This THC Honey Oil distillate is a universal product used in everything, including infused edibles, tinctures, creams and even vape cartridges. Its patented Hourglass™ cream is also manufactured exclusively at Grapefruit’s Coachillin lab facility by highly trained Grapefruit personnel.
  • Hourglass™ Topical THC+CBD Delivery Cream – The company’s patented Hourglass™ Topical Delivery Cream has solved the inherent difficulties of efficient skin absorption of THC and cannabinoids such as CBD, CBN, CBG and CBC, as well as hemp-derived CBDs and cannabinoids. Hourglass™ is a truly novel and disruptive delivery technology which fundamentally changes the way individuals will use THC and CBD to obtain their holistic benefits.*
  • Rainbow Dreams – Rainbow Dreams is the company’s lifestyle brand designed for the recreational cannabis marketplace. The brand captures the party-mode of the 1970s and offers vape carts with unique cannabis strains and natural flavors. The product fulfills an important marketplace niche – a top-shelf product that is competitively priced.

Market Outlook

The global cannabis market was valued at $10.6 billion in 2018. During the forecast period from 2019 to 2026, the market is expected to grow at a CAGR of 32.92%, reaching a projected value of $97.35 billion by the end of 2026 (https://nnw.fm/eTMSX).

Cannabis legalization has been gaining momentum around the world. Grapefruit is currently in a position to disrupt the industry – both the medicinal and recreational sectors – with proprietary products and manufacturing processes that harness the power of cutting-edge science and technology.

Management Team

Bradley J. Yourist is the Chief Executive Officer of Grapefruit. Mr. Yourist has been a follower of the medical cannabis market since the late 1990s, which allows him to understand the distribution model and the legal issues facing the market. He has also seen the benefit of cannabinoids in the medical industry. He understands the planning and operations of Grapefruit’s cannabis distribution arm and extraction lab and was instrumental in the planning for the facility.

Daniel J. Yourist is the Chief Operating Officer of Grapefruit. He is a licensed attorney in the state of California and a Real Estate Broker. Mr. Yourist is a licensing expert in the cannabis space and has gained extensive experience in all areas of managing a cannabis business in California. He ensures that every aspect of the company is run in accordance with state and local cannabis laws and regulations.

Grapefruit USA Inc. (OTCQB: GPFT), closed Tuesday's trading session at $0.165, up 10.00%, on 977,341 volume with 371 trades. The average volume for the last 3 months is 1,872,335 and the stock's 52-week low/high is $0.013624999/$0.310000002.

Recent News

Ideanomics Inc. (NASDAQ: IDEX)

The QualityStocks Daily Newsletter would like to spotlight Ideanomics Inc. (NASDAQ: IDEX).

Ideanomics (NASDAQ: IDEX) is a global company facilitating the adoption of commercial electric vehicles and supporting next-generation financial services and fintech products. Ideanomics is currently divided into two divisions – mobility and capital. These divisions provide shareholders with access to disruptive and high-growth opportunities.

Ideanomics Inc. (NASDAQ: IDEX) is a global company facilitating the adoption of commercial electric vehicles and supporting next-generation financial services and fintech products. Ideanomics is currently divided into two divisions – mobility and capital. These divisions provide shareholders with access to disruptive and high-growth opportunities.

The company expects 2021 to be another growth year after it raised approximately $400 million over the past six months. This funding has already been put to good use with acquisitions of Wireless Advanced Vehicle Electrification (WAVE) and Timios. With roughly $200 million still on the balance sheet, Ideanomics continues to look for new investments and acquisitions in revenue-based opportunities focused on EV and fintech businesses.

Founded in 2004, Ideanomics is headquartered in New York, New York, with additional offices in Hangzhou, Beijing and Qingdao, China. Its current operations span the United States, China, Ukraine and Malaysia.

Ideanomics Mobility

Ideanomics Mobility is focused on the EV market. The global commercial EV market was valued at $34.7 billion in 2018 and is expected to grow at a CAGR of 39.9% through 2022 to reach a total of $132.73 billion (https://ibn.fm/pPrf4). According to a survey by Grand View Research, the global EV charging infrastructure market is also expected to grow and reach $144.97 billion in 2028, expanding at a CAGR of 33.4% from 2021 to 2028.

This growth is expected to be driven by increased support of electric vehicles from the public, as well as the current U.S. administration, which has a goal of achieving a 100% clean-energy economy.

The Ideanomics Mobility unit consists of five companies:

  • Mobile Energy Global (MEG) – Wholly owned China-based service provider of the Sales-to-Finance-to-Charging (S2F2C) business model to assist commercial fleet operators on EV enablement. Recent sales include 2,000 units of D1, BYD’s custom electric ride-hailing vehicle.
  • Medici Motor Works – Wholly owned North America division. MMW will develop zero-emissions specialty vehicles, trucks, buses and vans for the North American market.
  • Wireless Advanced Vehicle Electrification (WAVE) – Wholly owned Utah-based commercial EV charging technology company with a specialized offering of in-ground wireless charging for commercial vehicles. WAVE’s chargers power the Antelope Valley Transportation Authority, the largest municipal EV bus system in the country. Its revenue for 2020 exceeded $7 million, and it boasts a robust pipeline for 2021 and beyond.
  • Treeletrik – Majority investment in Malaysian-based OEM will service a high-demand market – electric delivery mopeds. Treeletrik has obtained certifications in Thailand and Indonesia, with orders secured for 2021. Its North American marketing program is expected to commence in 2021. As a part of the ESG initiative, one tree will be planted for every unit sold.
  • Solectrac – Minority investment in California-based electric tractor company. Solectrac manufactures 100% electric tractors to benefit farmers, crops and the planet at a time when the agriculture market remains virtually unaddressed by EV solutions.
  • Silk EV – Minority investment in hyper car and performance car design company, which provides access to the high-end battery and charging technology development ecosystem.

Ideanomics is generating EV revenue from its Sales to Financing to Charging (S2F2C) business model, which features three operating areas:

  1. Vehicle and Battery Sales: Medici, Treeletrik and Solectrac cover three key market segments
  2. Financing, Leasing and Insurance: Offering financial services to fleet customers, commission delivery and origination fee-based revenue
  3. Charging and Energy Services: Offering charging as a service, battery swap programs and WAVE wireless charging products

Ideanomics Capital

Ideanomics Capital is focused on providing disruptive fintech solutions across the entire board of financial services, ranging from financial markets to digital securities and assets to mortgages and more. More mainstream institutions and a growing number of companies have increased their digital securities services, along with institutional investments boosting bitcoin and the emergence of favorable regulatory developments, creating ample opportunities for widespread adoption of financial technologies.

Additionally, the U.S. real estate industry is ripe for technologization, as it currently is fragmented, antiquated, opaque and largely untouched by tech innovation. However, the expanding market, with U.S. home sales expected to grow 21.9% in 2021, and the increased digitization of all business spaces are expected to promote a digital-first experience as the new industry standard this year and beyond (https://ibn.fm/DwsUv).

The Ideanomics Capital unit consists of five companies:

  • Timios – Wholly owned subsidiary bringing real estate into the 21st century by providing value-add, fee-based services addressing the title and closing process of home buying and mortgage transactions. Timios works to create transparency and efficiency within the market. Timios ended 2020 as a cash flow and EBITDA positive business.
  • The Delaware Board of Trade (DBOT) – Wholly owned FINRA-regulated ATS and broker dealer based in Delaware.
  • Liquefy – Minority investment bringing innovation to investment in real assets with blockchain technology by increasing efficiency in fractional ownership, lowering entry to investment barriers and unlocking liquidity in assets that were previously illiquid.
  • Technology Metals Market (TM2) – Minority investment in UK company delivering a direct investment and trading market for technology metals with a newly accessible technology metals asset class for inventory diversification. The traded metals are 100% backed by physical metals.
  • Intelligenta – Investment providing AI and machine learning solutions for financial institutions and regulators.

Management Team

Alf Poor is Ideanomics’ Chief Executive Officer. He is a client-focused and profit-driven executive who has a track record of success in rapidly growing technology companies and large, multi-national organizations. Mr. Poor’s expertise includes business planning, financing and creating and implementing corporate governance policies, as well as handling management across organizations. His specialization is working with cross-border and multi-national startups. Before taking the CEO role at Ideanomics, he was the CEO for Global Data Sentinel.

Conor McCarthy is the company’s Chief Financial Officer. He is a strategic and operationally oriented management-level professional. His extensive international experience is within the fintech, data science and advertising technology sectors. Mr. McCarthy has experience with public companies, PE, and VC-backed firms. His specializations are financial and management reporting, planning and analysis, financial modelling, performance metrics, KPIs, venture borrowing, Series A equity funding, ERP system implementation, international business operations, and acquisition due diligence and integration. Before joining Ideanomics, Mr. McCarthy most recently held a CFO position at OS33. Prior to that, he was CFO for Intent Media Inc.

Kate Lam is the company’s Managing Director of Financial Products. She is highly regarded for her fixed income capital marketing skills across Asia and the United States. Ms. Lam has over 25 years of experience in the financial markets industry, dealing with many asset classes and clients. Having spent a few years in the fintech startup industry, her skills bridge the gap between traditional financial assets and new technological innovations. She has held senior management positions at Bear Sterns, Deutsche Bank and Standard Chartered Bank.

Keith Byers is Ideanomics’ Senior Vice President of Operations. He has extensive experience managing strategic relationships with key clients and deepening the relationships through innovation and successful engagement strategies. Before Ideanomics, Mr. Byers was the Managing Partner and Head of Operations for Gain Theory. He has a Master of Arts – MA, Economics from Heriot-Watt University and a Master of Science – Economics from The University of Edinburgh.

Tony Sklar is the company’s Senior Vice President of Investor Relations. He is a communication strategist and has worked for multi-faceted companies with global operations. Mr. Sklar handles omni-channel distribution using intelligence platforms and data insights for strategic planning, international expansion and marketing channels. His specialties include project management with digital strategy and transformation, ICO, marketing, blockchain and strategic partnerships. In addition to his role with Ideanomics, he is also a board member for the Delaware Board of Trade and the host and senior technology reporter for Far From TV.

Ideanomics Inc. (IDEX), closed Tuesday's trading session at $3.38, off by 6.8871%, on 30,469,862 volume with 102,520 trades. The average volume for the last 3 months is 46,163,635 and the stock's 52-week low/high is $0.275999993/$5.5300002.

Recent News

HempFusion Wellness Inc. (TSX: CBD.U) (FWB: 8OO) (OTC: CBDHF)

The QualityStocks Daily Newsletter would like to spotlight HempFusion Wellness Inc. (TSX: CBD.U) (FWB: 8OO) (OTC: CBDHF).

HempFusion Wellness Inc. (TSX: CBD.U) (FWB: 8OO) (OTC: CBDHF) was highlighted today in a publication by Financial News Media, examining how, due to its healing properties, the demand for cannabidiol (CBD) for health and wellness purposes is high, which is the major factor driving the market growth. In addition, the rising acceptance and use of products due to government approvals is a major factor expected to boost production for CBD-infused products. 

HempFusion Wellness Inc. (TSX: CBD.U) (FWB: 8OO) (OTC: CBDHF) is a leader in the health and wellness CBD industry, providing innovative and diversified proprietary formulations utilizing the power of whole-food hemp nutrition.

Invested heavily in regulatory compliance, HempFusion aims to consistently meet and even exceed the high standards required by retailers and consumers – putting safety, quality and consistency first. In support of these efforts, the company is U.S. Hemp Authority Certified and is a current board member of the U.S. Hemp Roundtable, a coalition of leading companies committed to advancing safe hemp and CBD products.

HempFusion reported 1,750 shareholders and $18.3 million in cash as of June 30, 2020 – the second-largest cash position in its sector – with no debt. Looking ahead, the company is currently preparing to launch an IPO directly onto the Toronto Stock Exchange (“TSX”) senior board, where it has already reserved ticker symbol ‘CBD.U’. Learn More About HempFusion Upcoming IPO.

HempFusion is headquartered in Denver, Colorado.

HempFusion’s Proprietary Wellness Portfolio

The diverse product portfolio showcased by HempFusion includes 46 products that are currently on shelves. The company’s leading offerings include HempFusion-owned Biome Labs, HF Labs and Probulin. Due to the time and resources allocated to increasing the compliance of these proprietary products, HempFusion may have a competitive advantage and create additional retail opportunities that are not available for other CBD companies.

HempFusion’s Diversified Revenue Pipeline

HempFusion’s focus and investment into regulatory compliance has opened doors to major food and drug mass or big box retailers that are not available to other CBD companies. This strategic approach includes five distinct channels:

  • Natural Health Retailers
  • eCommerce
  • Big Box / Food and Drug Mass
  • Doctor Practitioner
  • Convenience

HempFusion’s Line of Products

HempFusion’s branded line of products is based on the company’s proprietary Whole Food Panoramic Full-Spectrum Hemp Complex. Each product is condition-specific, targeting needs such as sleep, energy and stress.

All of HempFusion’s products are made from DNA-verified, European Union registered, non-GMO, organic industrial hemp. The company’s offerings span multiple product categories, including:

  • Tinctures and capsules – These offerings make up the most popular product category in the $4 billion U.S. CBD market.
  • OTC topicals – HempFusion is one of the few CBD companies marketing FDA Drug Listed Topicals. The FDA compliance standards ensure that these products meet the standards set by larger national retailers.
  • Condition-specific OTC products – HempFusion has OTC products that are condition-specifically targeted, including:
    • OTC Pain Products – The global pain relief market for topicals is projected to reach $13.3 billion by 2025, with a CAGR from 2018 to 2025 of 7.4%.
    • OTC Eczema Products – The global dermatitis market is projected to reach $13.6 billion by 2026.
    • OTC Acne and Aging/Beauty Products – The global market for beauty and anti-aging products is currently estimated at $1.08 trillion.
    • OTC First Aid and Wound Healing Products – In 2019, the 10 top-selling first aid ointments in the United States generated over $650 million in sales.

Probulin Probiotics and Digestive Enzymes

Probulin Probiotics is a 100% wholly owned subsidiary of HempFusion Wellness Inc. and is currently one of the fastest growing probiotics brands in the United States, according to Spins syndicated data.

The Probulin product line addresses a wide range of consumer needs, including daily care, total care, women’s health and children’s products. The probiotics market represents a growing opportunity, as it is estimated to reach $7 billion globally by 2022.

Because of the diverse offerings of the Probulin line, it serves as HempFusion’s gateway to retailers who may not currently carry CBD products.

This ‘Trojan Horse Strategy’ is intended to allow the company to establish, develop and build relationships among these retailers. By achieving approved vendor status, the company may be able to facilitate faster onboarding times, enabling accelerated access to its CBD products in the future.

HF Labs and Biome Research – Doctor and Practitioner Product Lines

The HF Labs and Biome Research product lines are directed toward doctors and practitioners and cater to hospitals, compounding pharmacies and free-standing dispensaries. With an estimated target market of 28,000+ integrative medical doctors and 70,000+ licensed chiropractors in the United States, these offerings create a unique market opportunity as HempFusion continues to broaden its footprint in the CBD industry.

Research on CBD and Human Safety

HempFusion is one of 12 CBD companies selected to participate in ValidCare’s groundbreaking study regarding CBD and human safety, which is expected to be complete by the end of October 2020. The study is designed to address previous questions from the FDA regarding CBD products.

As part of this study, HempFusion and the other selected companies will be conducting human trials to determine if the daily use of full-spectrum hemp-derived CBD or CBD isolate impacts the human liver.

Management Team

Jason Mitchell, N.D., is the co-founder, Director and CEO of HempFusion. He has over 20 years of experience in the natural products industry and is a naturopathic doctor certified by the ANMCB. Mitchell received his doctorate from the Trinity College of Natural Health and is a member of the American Naturopathic Medical Association and the CNHP. He is an expert in supplemental formations and was responsible for successfully creating and launching over 300 industry-leading products during his 15-year tenure at Country Life Vitamins.

Ian DeQueiroz is the Chief of Brand Strategy & Partnerships and a Director for HempFusion. He is a serial entrepreneur with experience in early-stage cannabis and hemp companies. In 2010, he acquired his first cannabis CO2 extraction company in the United States. DeQueiroz has facilitated the licensing process for many companies in the United States, as well as one of Jamaica’s premier cannabis companies, Epican Medicinals Ltd.

Jon Visser is HempFusion’s Chief Revenue Officer. He has over 25 years of experience in all areas of sales and marketing, with a proven track record of consistently driving growth across all major channels. Visser was previously the Senior Vice President of Sales at Navajo Inc., a multi-national manufacturer/distributor of brands like Pennzoil Automotive Supplies, Piranha Eyewear and Navajo Inc., the largest distributor of trial- and travel-sized health and beauty products in the United States. Visser grew annual sales from $60 million to $128 million in less than three years while at Navajo Inc.

Bruce Valentine Jr. is the Chief Financial Officer of HempFusion. He has a proven track record working with high-growth companies and was named CFO of the Year in 2013 by the Northern Colorado Business Report. Valentine is the former CFO of Otter Products and has over 15 years of financial management experience.

Ola Lessard is the Chief Marketing Officer of HempFusion and is also the President of the U.S. Hemp Roundtable. She has experience in marketing creative and effective brand strategies. She is a former Vice President of Marketing at Barlean’s, an award-winning supplements provider based in Washington.

Nancy Angelini is the Director of the Doctor/Practitioner Channel. She has over 25 years as an active, licensed practitioner. Angelini travels the country as a lecturer and product manager. She is responsible for opening doors to some of the largest doctor/practitioner networks in the United States.

Daniel Brody is the Chief Corporate Officer of HempFusion. He is the co-founder and former Vice President of The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF). Brody has been instrumental in listing multiple world-class cannabis companies, including TGOD, Emblem Corp. and Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF). Before joining the cannabis industry, he spent seven years working at two leading Canadian brokerage firms.

HempFusion Wellness Inc. (CBDHF), closed Tuesday's trading session at $3.1715, off by 7.4825%, on 94,247 volume with 268 trades. The average volume for the last 3 months is 141,776 and the stock's 52-week low/high is $1.65999996/$3.69000005.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company that is currently specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, hopes to address this issue and improve the lives of GBM patients while also lowering recurrence risks with its lead drug candidate, Berubicin.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Tuesday's trading session at $2.74, off by 2.1429%, on 188,349 volume with 1,268 trades. The average volume for the last 3 months is 2,756,455 and the stock's 52-week low/high is $1.25820004/$5.61999988.

Recent News

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences (OTCQB: PBIO) (“PBI”), a developer of innovative, pressure-based solutions for the worldwide life sciences and other industries, and the College of Food, Agricultural, and Environmental Sciences (“CFAES”) at The Ohio State University (“Ohio State”) announced a wide-ranging agreement for the implementation of PBI’s patented Ultra Shear Technology(TM) (“UST”) platform. PBI is developing three different models of the UST processing instrument, named the BaroShear: a small footprint benchtop model, a medium capacity floor model, and an industrial scale, continuous flow model for high capacity. All three models are designed to perform high shear processing of liquids under controlled temperatures and pressure conditions. They will be set up for demonstration and hands-on use in the world-renowned Ohio State food pilot plant (https://ibn.fm/BxEdd).

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions — all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed Tuesday's trading session at $2.15, off by 6.5217%, on 7,647 volume with 18 trades. The average volume for the last 3 months is 26,193 and the stock's 52-week low/high is $1.19000005/$4.48999977.

Recent News

AzurRx BioPharma Inc. (NASDAQ: AZRX)

The QualityStocks Daily Newsletter would like to spotlight AzurRx BioPharma Inc. (NASDAQ: AZRX).

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced that its chairman and CEO, James Sapirstein, will participate in a “fireside chat” with Yi Chen, managing director, Equity Research at H.C. Wainwright, during the H.C. Wainwright Global Life Sciences Conference being held virtually March 9-11, 2021. To view the press release, visit: https://ibn.fm/apyHM

AzurRx BioPharma Inc. (AZRX) is a clinical-stage biopharmaceutical company focused on developing treatments for gastrointestinal diseases using recombinant proteins.

The company’s lead drug candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients suffering from cystic fibrosis and chronic pancreatitis.

AzurRx has already completed two Phase 2 clinical trials for MS1819 and is currently pursuing approval through parallel monotherapy and combination therapy pathways.

The company was founded in 2014 and is headquartered in New York City, with scientific operations in Langlade, France, and clinical operations in Hayward, California.

MS1819 Clinical Trials

The two current ongoing clinical trials for MS1819 in cystic fibrosis (CF) are the Phase 2b Option 2 monotherapy trial and the Phase 2 combination therapy trial, using MS1819 together with porcine pancreatic enzyme replacement therapy (PERT), the current standard of care. Pending the Phase 2b trial outcome, the company intends to initiate a Phase 3 trial in cystic fibrosis.

  • Phase 2b CF Option 2 Trial – The study was initiated in Q3 2020, using MS1819 doses in enteric capsule form (2240mg and 4480mg). Topline data for the trial is anticipated in Q1 2021.
  • Phase 2 CF Combination Trial – The study was initiated in Q4 2019, using daily dose levels of PERT in combination with MS1819 dosages (700mg, 1120mg and 2240mg). Topline data is anticipated in Q2 2021.

These trials are currently addressing the treatment of EPI in patients with cystic fibrosis and chronic pancreatitis – an established global market with an estimated value in excess of $2 billion that has been growing at a CAGR greater than 20% over the past five years.

Results from AzurRx’s Phase 2b Option 2 trial of MS1819 in cystic fibrosis patients demonstrate that the non-porcine MS1819 lipase is well-tolerated by patients, with no significant safety signals observed at the 2240mg daily dose level.

“[W]e have evaluated four different enteric capsules and identified the best suitable formulation for MS1819 that provides gastroprotection of enzyme content and delayed release into the duodenum,” James Sapirstein, President & CEO of AzurRx, stated in a September 2020 news release (https://ibn.fm/27t4W). “Our clinical program continues to advance, and we are determined to develop MS1819 as a safer alternative to porcine pancreatic enzyme replacement therapy, significantly reducing the pill burden of cystic fibrosis patients.”

Financial Highlights

As of July 2020, AzurRx had raised gross cash capital of $22.1 million, including $15.2 million from Series B convertible preferred stock and warrants in July 2020 and $6.9 million from convertible promissory notes and warrants in December 2019 and January 2020. Notably, AzurRx solidified its financial position and created an effectively debt-free balance sheet by exchanging substantially all of its outstanding convertible notes into the Series B convertible preferred stock financing.

The company secured an additional $2.5 million in French Research Tax Credits, received in 2020, for the years 2017-2019 (https://ibn.fm/Qxk7O).

In a letter to shareholder, Sapirstein noted that ensuring the company maintains sufficient capital to support its business operations has been a key focus. He further stated that the company is in “a financially secure position” to complete its two Phase 2 MS1819 clinical trial programs and to begin preparations in 2021 for a pivotal Phase 3 study.

The company has no current plans to access additional financing, as it believes it has enough cash to fund existing operational and clinical objectives through Q3 2021.

Management Team

James Sapirstein is the President and CEO of AzurRx BioPharma. He was previously the CEO and a board member for ContraVir Pharmaceuticals Inc., which is now known as Hepion Pharmaceuticals Inc. (NASDAQ: HEPA). Mr. Sapirstein has almost 36 years of experience in the pharmaceutical industry, with expertise in drug development and commercialization. He currently serves on the Emerging Companies and Health Section boards of the BIO (Biotechnology Innovation Organization) and is Chairman Emeritus of BioNJ. He earned his Bachelor’s degree in Pharmacy from Rutgers University and has an MBA in management from Fairleigh Dickinson University.

Daniel Schneiderman is the Chief Financial Officer of AzurRx. He previously served as the CFO of Biophytis SA and its U.S. subsidiary, Biophytis, Inc., clinical-stage biotechnology companies focused on the development of pharmaceutical candidates for age-related diseases. He was appointed to the AzurRx position in January 2020, bringing to the team over 18 years of experience in capital markets and finance operations. Mr. Schneiderman holds a degree in economics from Tulane University.

James Pennington, M.D., is the Chief Medical Officer of AzurRx. Before joining the team, he was the Chief Medical Officer and Senior Clinical Fellow for 11 years at Anthera Pharmaceuticals. Before becoming a part of the biotech industry, Dr. Pennington was on the Medical Faculty of Harvard Medical School for 10 years. He received his medical degree from Oregon Health & Science University.

Martin Krusin is the Senior Vice President for Corporate Development at AzurRx. He has 20 years of experience in business development, strategic marketing, financing and operations in the health care, financial services and consulting sectors. Before joining AzurRx, he was the VP for Business Development at FluoroPharma Medical Inc. Mr. Krusin received his MBA from Columbia Business School in finance and marketing, an MPhil. in political economy from Oxford University and a BA in international relations from Swarthmore College.

Dinesh Srinivasan, Ph.D., is the Vice President for Translational Research at AzurRx. He has over 15 years of experience leading drug discovery and development in the pharmaceutical industry. He began his career as a post-doctorate fellow at Roche Palo Alto. Dr. Srinivasan received his MSc in Biotechnology from the University of Mumbai, India, and a Ph.D. in Pharmacology and Toxicology from the University of Arizona – Tucson.

Ted Stover is the Product Development Director at AzurRx. He joined the company in 2020 to oversee CMC and Project Management. Before joining AzurRx, he spent 20 years focused on manufacturing operations and analytical method development for all stages of pharmaceutical drug development. Mr. Stover earned his MBA from the University of Florida.

AzurRx BioPharma Inc. (AZRX), closed Tuesday's trading session at $1.39, off by 7.3333%, on 1,433,816 volume with 3,736 trades. The average volume for the last 3 months is 8,146,605 and the stock's 52-week low/high is $0.370867997/$2.63000011.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

closed Monday's trading